Evidence map›Paper›PMID 27093859›Full record

ArticleMalaria journal2016

Differential kinetic profiles and metabolism of primaquine enantiomers by human hepatocytes.

Pius S Fasinu, Bharathi Avula, Babu L Tekwani, N P Dhammika Nanayakkara, Yan-Hong Wang, H M T Bandara Herath, James D McChesney, Gregory A Reichard, Sean R Marcsisin, Mahmoud A Elsohly and 3 more

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in Malaria journal, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02898779 (Development of Safer Drugs for Malaria in U.S. Troops, Civilian Personnel, and Travelers), which is not on this map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
3.9field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02898779 phase1completednot on this mapstarted 2017, after this paper: background citation

Development of Safer Drugs for Malaria in U.S. Troops, Civilian Personnel, and Travelers: Clinical Evaluation of Primaquine Enantiomer

TypeinterventionalSponsorUniversity of Mississippi, OxfordRan2017 to 2018Enrolled36ConditionsMalariaArmsPrimaquine, R-Primaquine, S-Primaquine, SR Primaquine
3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 24 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Review
  4. Differential impact of Tafenoquine and Primaquine onAntimicrobial agents and chemotherapy · 2026
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Pharmacogenomics · 2022
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Frontiers in pharmacology · 2021
    Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Pius S FasinuThe National Center for Natural Products Research, School of Pharmacy, The University of Mississippi, University, MS, 38677, USA.
Bharathi AvulaThe National Center for Natural Products Research, School of Pharmacy, The University of Mississippi, University, MS, 38677, USA.
Babu L TekwaniThe National Center for Natural Products Research, School of Pharmacy, The University of Mississippi, University, MS, 38677, USA.
N P Dhammika NanayakkaraThe National Center for Natural Products Research, School of Pharmacy, The University of Mississippi, University, MS, 38677, USA.
Yan-Hong WangThe National Center for Natural Products Research, School of Pharmacy, The University of Mississippi, University, MS, 38677, USA.
H M T Bandara HerathThe National Center for Natural Products Research, School of Pharmacy, The University of Mississippi, University, MS, 38677, USA.
James D McChesneyIronstone Separations, Inc., Etta, Oxford, MS, 38627, USA.
Gregory A ReichardMilitary Malaria Research Program, Experimental Therapeutics Branch, Walter Reed Army Institute of Research, 503 Robert Grant Ave, Silver Spring, MD, 20910, USA.
Sean R MarcsisinMilitary Malaria Research Program, Experimental Therapeutics Branch, Walter Reed Army Institute of Research, 503 Robert Grant Ave, Silver Spring, MD, 20910, USA.
Mahmoud A ElsohlyThe National Center for Natural Products Research, School of Pharmacy, The University of Mississippi, University, MS, 38677, USA.
Shabana I KhanThe National Center for Natural Products Research, School of Pharmacy, The University of Mississippi, University, MS, 38677, USA.
Ikhlas A KhanThe National Center for Natural Products Research, School of Pharmacy, The University of Mississippi, University, MS, 38677, USA.
Larry A WalkerThe National Center for Natural Products Research, School of Pharmacy, The University of Mississippi, University, MS, 38677, USA. lwalker@olemiss.edu.
University of Mississippi · USWalter Reed Army Institute of Research · USZirChrom Separations (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe clinical utility of primaquine (PQ), used as a racemic mixture of two enantiomers, is limited due to metabolism-linked hemolytic toxicity in individuals with genetic deficiency in glucose-6-phosphate dehydrogenase. The current study investigated differential metabolism of PQ enantiomers in light of the suggestions that toxicity and efficacy might be largely enantioselective.

methodsStable isotope (13)C-labelled primaquine and its two enantiomers (+)-PQ, (-)-PQ were separately incubated with cryopreserved human hepatocytes. Time-tracked substrate depletion and metabolite production were monitored via UHPLC-MS/MS.

resultsThe initial half-life of 217 and 65 min; elimination rate constants (λ) of 0.19 and 0.64 h(-1); intrinsic clearance (Clint) of 2.55 and 8.49 (µL/min)/million cells, which when up-scaled yielded Clint of 6.49 and 21.6 (mL/min)/kg body mass was obtained respectively for (+)- and (-)-PQ. The extrapolation of in vitro intrinsic clearance to in vivo human hepatic blood clearance, performed using the well-stirred liver model, showed that the rate of hepatic clearance of (+)-PQ was only 45 % that of (-)-PQ. Two major primary routes of metabolism were observed-oxidative deamination of the terminal amine and hydroxylations on the quinoline moiety of PQ. The major deaminated metabolite, carboxyprimaquine (CPQ) was preferentially generated from the (-)-PQ. Other deaminated metabolites including PQ terminal alcohol (m/z 261), a cyclized side chain derivative from the aldehyde (m/z 241), cyclized carboxylic acid derivative (m/z 257), a quinone-imine product of hydroxylated CPQ (m/z 289), CPQ glucuronide (m/z 451) and the glucuronide of PQ alcohol (m/z 437) were all preferentially generated from the (-)-PQ. The major quinoline oxidation product (m/z 274) was preferentially generated from (+)-PQ. In addition to the products of the two metabolic pathways, two other major metabolites were observed: a prominent glycosylated conjugate of PQ on the terminal amine (m/z 422), peaking by 30 min and preferentially generated by (+)-PQ; and the carbamoyl glucuronide of PQ (m/z 480) exclusively generated from (+)-PQ.

conclusionMetabolism of PQ showed enantioselectivity. These findings may provide important information in establishing clinical differences in PQ enantiomers.

Indexed as

Carbon IsotopesChromatography, High Pressure LiquidHalf-LifeHepatocytesHumansKineticsPrimaquineStereoisomerismTandem Mass Spectrometry8-(3-carboxy-1-methylpropylamino)-6-methoxyquinolineCarbon IsotopesPrimaquineEnantioselectivityHepatocytesMalariaMetabolismPrimaquine enantiomersPrimaquine metabolites

Identifiers

PMID27093859
PMCPMC4837544
OpenAlexW2341399566

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.